{"id":"https://openalex.org/W4404792132","doi":"https://doi.org/10.33590/microbiolinfectdisamj/twwj7227","title":"Ibalizumab\u2019s Role in Multidrug-Resistant HIV","display_name":"Ibalizumab\u2019s Role in Multidrug-Resistant HIV","publication_year":2024,"publication_date":"2024-11-28","ids":{"openalex":"https://openalex.org/W4404792132","doi":"https://doi.org/10.33590/microbiolinfectdisamj/twwj7227"},"language":"en","primary_location":{"id":"doi:10.33590/microbiolinfectdisamj/twwj7227","doi":"https://doi.org/10.33590/microbiolinfectdisamj/twwj7227","is_oa":true,"landing_page_url":"http://dx.doi.org/10.33590/microbiolinfectdisamj/twwj7227","pdf_url":"https://www.emjreviews.com/wp-content/uploads/2024/11/Ibalizumabs-Role-in-Multidrug-Resistant-HIV-2.pdf","source":{"id":"https://openalex.org/S4404677245","display_name":"Microbiology & infectious diseases :","issn_l":"2977-4055","issn":["2977-4055"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Medical Journal Microbiology and Infectious Diseases","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.emjreviews.com/wp-content/uploads/2024/11/Ibalizumabs-Role-in-Multidrug-Resistant-HIV-2.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027590697","display_name":"Eleanor Roberts","orcid":"https://orcid.org/0000-0003-2711-1934","observed_orcids":["https://orcid.org/0000-0003-2711-1934"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Eleanor Roberts","raw_affiliation_strings":["Beeline Science Communications, Ltd, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Beeline Science Communications, Ltd, UK","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5027590697"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.27162207,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0026000000070780516,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ibalizumab","display_name":"ibalizumab","score":1.0},{"id":"https://openalex.org/keywords/multidrug-resistant-hiv","display_name":"multidrug-resistant HIV","score":0.9980000257492065},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.7649999856948853},{"id":"https://openalex.org/keywords/lenacapavir","display_name":"lenacapavir","score":0.9490000009536743},{"id":"https://openalex.org/keywords/capsid-inhibitor","display_name":"capsid inhibitor","score":0.8949999809265137},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.9440000057220459},{"id":"https://openalex.org/keywords/baseline-demographics","display_name":"baseline demographics","score":0.5410000085830688},{"id":"https://openalex.org/keywords/hiv-treatment","display_name":"HIV treatment","score":0.4359999895095825}],"concepts":[{"id":"https://openalex.org/C133936738","wikidata":"https://www.wikidata.org/wiki/Q643839","display_name":"Multiple drug resistance","level":3,"score":0.7562700510025024},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.7087233066558838},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.5094802975654602},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38211825489997864},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.24162566661834717},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.22413423657417297},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.13315650820732117}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.33590/microbiolinfectdisamj/twwj7227","doi":"https://doi.org/10.33590/microbiolinfectdisamj/twwj7227","is_oa":true,"landing_page_url":"http://dx.doi.org/10.33590/microbiolinfectdisamj/twwj7227","pdf_url":"https://www.emjreviews.com/wp-content/uploads/2024/11/Ibalizumabs-Role-in-Multidrug-Resistant-HIV-2.pdf","source":{"id":"https://openalex.org/S4404677245","display_name":"Microbiology & infectious diseases :","issn_l":"2977-4055","issn":["2977-4055"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Medical Journal Microbiology and Infectious Diseases","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.33590/microbiolinfectdisamj/twwj7227","doi":"https://doi.org/10.33590/microbiolinfectdisamj/twwj7227","is_oa":true,"landing_page_url":"http://dx.doi.org/10.33590/microbiolinfectdisamj/twwj7227","pdf_url":"https://www.emjreviews.com/wp-content/uploads/2024/11/Ibalizumabs-Role-in-Multidrug-Resistant-HIV-2.pdf","source":{"id":"https://openalex.org/S4404677245","display_name":"Microbiology & infectious diseases :","issn_l":"2977-4055","issn":["2977-4055"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"American Medical Journal Microbiology and Infectious Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"display_name":"Good health and well-being","score":0.8399999737739563,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320312382","display_name":"ViiV Healthcare","ror":"https://ror.org/01cc9yk21"},{"id":"https://openalex.org/F4320319071","display_name":"Moderna","ror":"https://ror.org/01xm4wg91"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4404792132.pdf","grobid_xml":"https://content.openalex.org/works/W4404792132.grobid-xml"},"referenced_works_count":9,"referenced_works":["https://openalex.org/W2513882531","https://openalex.org/W2887987288","https://openalex.org/W2922274842","https://openalex.org/W3119448726","https://openalex.org/W3206066052","https://openalex.org/W4233731496","https://openalex.org/W4238075886","https://openalex.org/W4389574586","https://openalex.org/W4402354459"],"related_works":["https://openalex.org/W2899084033","https://openalex.org/W2748952813","https://openalex.org/W3031052312","https://openalex.org/W4389568370","https://openalex.org/W3032375762","https://openalex.org/W1995515455","https://openalex.org/W2080531066","https://openalex.org/W3108674512","https://openalex.org/W1506200166","https://openalex.org/W1489783725"],"abstract_inverted_index":{"Although":[0],"treatment":[1],"for":[2,42],"HIV":[3,15,47,128,143],"has":[4,48],"advanced":[5],"considerably":[6],"over":[7],"the":[8,98,155,160,178,190],"decades,":[9],"there":[10],"are":[11,196],"still":[12],"people":[13,43],"with":[14,44,67,159],"that":[16,30,82,111,133],"is":[17,36,78],"resistant":[18],"to":[19,129,199],"multiple":[20],"antiretroviral":[21],"therapies":[22],"(ART).":[23],"Ibalizumab,":[24],"a":[25,37,72,168],"humanized":[26],"IgG4":[27],"monoclonal":[28],"antibody":[29],"gained":[31],"orphan":[32],"status":[33],"in":[34,51,71,154,167],"2018,":[35],"post-attachment":[38],"inhibitor":[39,180],"whose":[40],"efficacy":[41,86],"multidrug-resistant":[45],"(MDR)":[46],"been":[49],"demonstrated":[50],"Phase":[52],"II":[53],"and":[54,59,68,87,123,149,163],"III":[55],"trials.":[56],"The":[57],"Prospective":[58],"Retrospective":[60],"Observational":[61],"Study":[62],"of":[63,89,107,127,170,193],"Multidrug-Resistant":[64],"Patient":[65],"Outcomes":[66],"without":[69],"Ibalizumab":[70],"Real-World":[73],"Setting:":[74],"United":[75],"States":[76],"(PROMISE-US)":[77],"an":[79,92],"ongoing":[80],"study":[81],"will":[83],"investigate":[84],"long-term":[85],"durability":[88],"ibalizumab":[90,114,137],"plus":[91],"optimized":[93],"background":[94],"regimen":[95],"(OBR).":[96],"In":[97],"poster":[99],"discussed":[100],"here,":[101],"presented":[102],"at":[103,165],"IDWeek":[104],"2024,":[105],"examination":[106],"baseline":[108,142,166],"demographics":[109],"showed":[110],"individuals":[112,194],"prescribed":[113,177,201],"(IBA":[115],"group)":[116],"had":[117],"similar":[118],"mean":[119,141],"age,":[120],"sex,":[121],"race,":[122],"duration":[124],"since":[125],"diagnosis":[126],"those":[130],"on":[131],"regimens":[132],"did":[134],"not":[135],"include":[136],"(non-IBA":[138],"group).":[139],"However,":[140],"RNA":[144],"copies/mL":[145],"were":[146,175],"much":[147],"higher":[148],"CD4+":[150],"T":[151],"cells/mm3":[152],"lower":[153],"IBA":[156,171],"group":[157,172],"compared":[158],"non-IBA":[161],"group,":[162],"highest/lowest":[164],"subset":[169],"patients":[173],"who":[174,195],"also":[176,183],"capsid":[179],"lenacapavir.":[181],"OBR":[182],"differed":[184],"between":[185],"groups.":[186],"These":[187],"results":[188],"highlight":[189],"HIV-related":[191],"characteristics":[192],"more":[197],"likely":[198],"be":[200],"ibalizumab.":[202]},"counts_by_year":[],"updated_date":"2026-09-27T08:07:27.782135","created_date":"2025-10-10T00:00:00"}